Adamis Pharmaceuticals Corporation Issues Nationwide Voluntary Recall of SYMJEPI® (Epinephrine) Injection for Potential Manufacturing Defect

Date: 03/22/2022

Product Type: Defect, Drugs

Company Announcement Date: March 21, 2022

FDA Publish Date:  March 22, 2022

Product Type:  Drugs

Reason for Announcement: Potential clogging of the needle preventing the dispensing of epinephrine

Company Name: Adamis Pharmaceuticals Corporation

Brand Name: Adamis Pharmaceuticals Corporation

Product Description:SYMJEPI (epinephrine) Injection 0.15 mg (0.15 mg/0.3 mL) and 0.3 mg (0.3 mg/0.3 mL) Pre-Filled Single-Dose Syringes

USA-FDA Link: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/adamis-pharmaceuticals-corporation-issues-nationwide-voluntary-recall-symjepir-epinephrine-injection